1
|
Antoni S, Ferlay J, Soerjomataram I, Znaor
A, Jemal A and Bray F: Bladder cancer incidence and mortality: A
global overview and recent trends. Eur Urol. 71:96–108. 2017.
View Article : Google Scholar : PubMed/NCBI
|
2
|
David KA, Mallin K, Milowsky MI, Ritchey
J, Carroll PR and Nanus DM: Surveillance of urothelial carcinoma:
Stage and grade migration, 1993–2005 and survival trends,
1993–2000. Cancer. 115:1435–1447. 2009. View Article : Google Scholar : PubMed/NCBI
|
3
|
Yang MH, Chen KK, Yen CC, Wang WS, Chang
YH, Huang WJ, Fan FS, Chiou TJ, Liu JH and Chen PM: Unusually high
incidence of upper urinary tract urothelial carcinoma in Taiwan.
Urology. 59:681–687. 2002. View Article : Google Scholar : PubMed/NCBI
|
4
|
Stiborová M, Frei E, Breuer A, Bieler CA
and Schmeiser HH: Aristolactam I a metabolite of aristolochic acid
I upon activation forms an adduct found in DNA of patients with
chinese herbs nephropathy. Exp Toxicol Pathol. 51:421–427. 1999.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Arlt VM, Stiborova M and Schmeiser HH:
Aristolochic acid as a probable human cancer hazard in herbal
remedies: A review. Mutagenesis. 17:265–277. 2002. View Article : Google Scholar : PubMed/NCBI
|
6
|
Deng CX: BRCA1: Cell cycle checkpoint,
genetic instability, DNA damage response and cancer evolution.
Nucleic Acids Res. 34:1416–1426. 2006. View Article : Google Scholar : PubMed/NCBI
|
7
|
Cosyns JP, Jadoul M, Squifflet JP, Wese FX
and van Ypersele de Strihou C: Urothelial lesions in Chinese-herb
nephropathy. Am J Kidney Dis. 33:1011–1017. 1999. View Article : Google Scholar : PubMed/NCBI
|
8
|
Rouprêt M, Babjuk M, Compérat E, Zigeuner
R, Sylvester RJ, Burger M, Cowan NC, Böhle A, Van Rhijn BW,
Kaasinen E, et al: European association of urology guidelines on
upper urinary tract urothelial cell carcinoma: 2015 update. Eur
Urol. 68:868–879. 2015. View Article : Google Scholar : PubMed/NCBI
|
9
|
Margulis V, Shariat SF, Matin SF, Kamat
AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD and Wood CG:
Upper Tract Urothelial Carcinoma Collaboration The Upper Tract
Urothelial Carcinoma Collaboration: Outcomes of radical
nephroureterectomy: A series from the Upper Tract Urothelial
Carcinoma Collaboration. Cancer. 115:1224–1233. 2009. View Article : Google Scholar : PubMed/NCBI
|
10
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Abouassaly R, Alibhai SM, Shah N,
Timilshina N, Fleshner N and Finelli A: Troubling outcomes from
population-level analysis of surgery for upper tract urothelial
carcinoma. Urology. 76:895–901. 2010. View Article : Google Scholar : PubMed/NCBI
|
12
|
Audenet F, Yates DR, Cussenot O and
Rouprêt M: The role of chemotherapy in the treatment of urothelial
cell carcinoma of the upper urinary tract (UUT-UCC). Urol Oncol.
31:407–413. 2013. View Article : Google Scholar : PubMed/NCBI
|
13
|
Sternberg CN, Yagoda A, Scher HI, Watson
RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N,
et al: Methotrexate, vinblastine, doxorubicin, and cisplatin for
advanced transitional cell carcinoma of the urothelium. Efficacy
and patterns of response and relapse. Cancer. 64:2448–2458. 1989.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Freiha F, Reese J and Torti FM: A
randomized trial of radical cystectomy versus radical cystectomy
plus cisplatin, vinblastine and methotrexate chemotherapy for
muscle invasive bladder cancer. J Urol. 155:495–500. 1996.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Koppie TM, Shariat SF, Nelson EC, Margulis
V, Remzi M, Montorsi F, Raman JD, Ziguener R, Suardi N, Weizer AZ,
et al: Adjuvant chemotherapy for upper tract transitional cell
carcinoma: Results from the Upper Tract UCC Consortium. J Urol.
179:1192008. View Article : Google Scholar
|
16
|
Kwak C, Lee SE, Jeong IG and Ku JH:
Adjuvant systemic chemotherapy in the treatment of patients with
invasive transitional cell carcinoma of the upper urinary tract.
Urology. 68:53–57. 2006. View Article : Google Scholar : PubMed/NCBI
|
17
|
Kondo T, Nakazawa H, Ito F, Hashimoto Y,
Toma H and Tanabe K: Primary site and incidence of lymph node
metastases in urothelial carcinoma of upper urinary tract. Urology.
69:265–269. 2007. View Article : Google Scholar : PubMed/NCBI
|
18
|
Sobin LH, Gospodarowicz MK and Wittekind
C: Renal pelvis and ureter. TNM Online. 258–261. 2010.https://doi.org/10.1002/9780471420194.tnmc43.pub2
View Article : Google Scholar
|
19
|
Lopez-Beltran A, Bassi P, Pavone-Macaluso
M and Montironi R: Handling and pathology reporting of specimens
with carcinoma of the urinary bladder, ureter, and renal pelvis.
Eur Urol. 45:257–266. 2004. View Article : Google Scholar : PubMed/NCBI
|
20
|
Saito K, Kawakami S, Fujii Y, Sakura M,
Masuda H and Kihara K: Lymphovascular invasion is independently
associated with poor prognosis in patients with localized upper
urinary tract urothelial carcinoma treated surgically. J Urol.
178:2291–2296. 2007. View Article : Google Scholar : PubMed/NCBI
|
21
|
National Kidney Foundation: K/DOQI
clinical practice guidelines for chronic kidney disease:
Evaluation, classification, and stratification. Am J Kidney Dis. 39
2 Suppl 1:S1–S266. 2002.PubMed/NCBI
|
22
|
Hsiao PJ, Hsieh PF, Chang CH, Wu HC, Yang
CR and Huang CP: Higher risk of urothelial carcinoma in the upper
urinary tract than in the urinary bladder in hemodialysis patients.
Ren Fail. 38:663–670. 2016. View Article : Google Scholar : PubMed/NCBI
|
23
|
Ho GY, Woodward N and Coward JI: Cisplatin
versus carboplatin: Comparative review of therapeutic management in
solid malignancies. Crit Rev Oncol Hematol. 102:37–46. 2016.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Dreicer R, Manola J, Roth BJ, See WA,
Kuross S, Edelman MJ, Hudes GR and Wilding G: Phase III trial of
methotrexate, vinblastine, doxorubicin, and cisplatin versus
carboplatin and paclitaxel in patients with advanced carcinoma of
the urothelium. Cancer. 100:1639–1645. 2004. View Article : Google Scholar : PubMed/NCBI
|
25
|
Leow JJ, Martin-Doyle W, Fay AP, Choueiri
TK, Chang SL and Bellmunt J: A systematic review and meta-analysis
of adjuvant and neoadjuvant chemotherapy for upper tract urothelial
carcinoma. Eur Urol. 66:529–541. 2014. View Article : Google Scholar : PubMed/NCBI
|
26
|
Vassilakopoulou M, de la Motte Rouge T,
Colin P, Ouzzane A, Khayat D, Dimopoulos MA, Papadimitriou CA,
Bamias A, Pignot G, Nouhaud FX, et al: Outcomes after adjuvant
chemotherapy in the treatment of high-risk urothelial carcinoma of
the upper urinary tract (UUT-UC): Results from a large multicenter
collaborative study. Cancer. 117:5500–5508. 2011. View Article : Google Scholar : PubMed/NCBI
|
27
|
Hellenthal NJ, Shariat SF, Margulis V,
Karakiewicz PI, Roscigno M, Bolenz C, Remzi M, Weizer A, Zigeuner
R, Bensalah K, et al: Adjuvant chemotherapy for high risk upper
tract urothelial carcinoma: Results from the Upper Tract Urothelial
Carcinoma Collaboration. J Urol. 182:900–906. 2009. View Article : Google Scholar : PubMed/NCBI
|
28
|
Soga N, Arima K and Sugimura Y: Adjuvant
methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy
has potential to prevent recurrence of bladder tumors after
surgical removal of upper urinary tract transitional cell
carcinoma. Int J Urol. 15:800–803. 2008. View Article : Google Scholar : PubMed/NCBI
|
29
|
Koie T, Ohyama C, Hashimoto Y, Hatakeyama
S, Yamamoto H, Yoneyama T and Kamimura N: Efficacies and safety of
neoadjuvant gemcitabine plus carboplatin followed by immediate
cystectomy in patients with muscle-invasive bladder cancer,
including those unfit for cisplatin: A prospective single-arm
study. Int J Clin Oncol. 18:724–730. 2013. View Article : Google Scholar : PubMed/NCBI
|
30
|
Mertens LS, Meijer RP, Kerst JM, Bergman
AM, van Tinteren H, van Rhijn BW and Horenblas S: Carboplatin based
induction chemotherapy for nonorgan confined bladder cancer-a
reasonable alternative for cisplatin unfit patients? J Urol.
188:1108–1113. 2012. View Article : Google Scholar : PubMed/NCBI
|